​

Bio-Rad Laboratories (BIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIO Stock Forecast

Bio-Rad Laboratories (BIO) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $482.50, with a high of $565.00 and a low of $400.00. This represents a 99.12% increase from the last price of $242.32.

$200 $280 $360 $440 $520 $600 High: $565 Avg: $482.5 Low: $400 Last Closed Price: $242.32

BIO Stock Rating

Bio-Rad Laboratories stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (72.73%), 3 Hold (27.27%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 3 8 Strong Sell Sell Hold Buy Strong Buy

BIO Price Target Upside V Benchmarks

TypeNameUpside
StockBio-Rad Laboratories99.12%
SectorHealthcare Stocks 30.37%
IndustryMedical Device Stocks19.97%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$400.00
Last Closing Price$242.32$242.32$242.32
Upside/Downside--65.07%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25222--6
Mar, 25222--6
Feb, 25222--6
Jan, 25222--6
Dec, 24222--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 01, 2024Patrick DonnellyCitigroup$400.00$338.5818.14%65.07%
Dec 07, 2022RBC Capital$565.00$399.5941.39%133.16%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024RBC CapitalOutperformOutperformhold
Oct 31, 2024CitigroupBuyBuyhold
Oct 01, 2024Wells FargoBuyBuyhold
Oct 01, 2024CitigroupNeutralBuyupgrade
Aug 27, 2024Wells FargoEqual-Weightinitialise
Jun 03, 2024JefferiesHolddowngrade
Apr 03, 2024CitigroupNeutraldowngrade
Dec 07, 2022RBC CapitalOutperforminitialise

Financial Forecast

EPS Forecast

$-150 $-90 $-30 $30 $90 $150 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$127.86$142.61$-121.79$-21.82$-65.36----
Avg Forecast$9.81$15.31$14.39$11.48$10.29$11.51$13.08$15.10$17.35
High Forecast$9.86$15.39$14.50$11.58$10.34$11.54$13.19$15.22$17.49
Low Forecast$9.74$15.20$14.28$11.40$10.23$11.47$12.99$14.99$17.22
Surprise %1203.36%831.48%-946.35%-290.07%-735.18%----

Revenue Forecast

$2B $3B $3B $3B $3B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.55B$2.92B$2.80B$2.67B$2.57B----
Avg Forecast$2.44B$2.89B$2.82B$2.68B$2.58B$2.65B$2.78B$2.92B$3.07B
High Forecast$2.45B$2.90B$2.83B$2.69B$2.59B$2.67B$2.78B$2.93B$3.09B
Low Forecast$2.43B$2.87B$2.80B$2.66B$2.56B$2.64B$2.78B$2.91B$3.05B
Surprise %4.22%1.27%-0.51%-0.16%-0.48%----

Net Income Forecast

$-4B $-2B $-600M $1B $3B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.81B$4.25B$-3.63B$-637.32M$-1.84B----
Avg Forecast$2.89B$2.27B$-2.01B$-637.32M$300.42M$336.13M$382.24M$441.19M$506.78M
High Forecast$3.47B$3.28B$-696.16M$-220.77M$302.16M$337.14M$385.18M$444.58M$510.83M
Low Forecast$2.31B$1.26B$-3.32B$-1.05B$298.67M$335.11M$379.29M$437.79M$503.03M
Surprise %32.01%87.55%80.50%--713.88%----

BIO Forecast FAQ

Is Bio-Rad Laboratories stock a buy?

Bio-Rad Laboratories stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bio-Rad Laboratories is a favorable investment for most analysts.

What is Bio-Rad Laboratories's price target?

Bio-Rad Laboratories's price target, set by 11 Wall Street analysts, averages $482.5 over the next 12 months. The price target range spans from $400 at the low end to $565 at the high end, suggesting a potential 99.12% change from the previous closing price of $242.32.

How does Bio-Rad Laboratories stock forecast compare to its benchmarks?

Bio-Rad Laboratories's stock forecast shows a 99.12% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the medical device stocks industry (19.97%).

What is the breakdown of analyst ratings for Bio-Rad Laboratories over the past three months?

  • April 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Bio-Rad Laboratories’s EPS forecast?

Bio-Rad Laboratories's average annual EPS forecast for its fiscal year ending in December 2025 is $11.51, marking a -117.61% decrease from the reported $-65.36 in 2024. Estimates for the following years are $13.08 in 2026, $15.1 in 2027, and $17.35 in 2028.

What is Bio-Rad Laboratories’s revenue forecast?

Bio-Rad Laboratories's average annual revenue forecast for its fiscal year ending in December 2025 is $2.65B, reflecting a 3.45% increase from the reported $2.57B in 2024. The forecast for 2026 is $2.78B, followed by $2.92B for 2027, and $3.07B for 2028.

What is Bio-Rad Laboratories’s net income forecast?

Bio-Rad Laboratories's net income forecast for the fiscal year ending in December 2025 stands at $336.13M, representing a -118.23% decrease from the reported $-1.844B in 2024. Projections indicate $382.24M in 2026, $441.19M in 2027, and $506.78M in 2028.